|
|
Karin Jurkat-Rott, Frank Lehmann-Horn
J Clin Invest. 2005;
115(8):2000
doi:10.1172/JCI25525
Abstract |
Full text
| PDF
M
uscle channelopathies are caused by mutations in ion channel genes, by antibodies directed against ion channel proteins, or by changes of cell homeostasis leading to aberrant splicing of ion channel RNA or to disturbances of modification and localization of channel proteins. As ion channels constitute one of the only protein families that allow functional examination on the molecular level, expression studies of putative mutations have become standard in confirming that the mutations cause disease. Functional changes may not necessarily prove disease causality of a putative mutation but could be brought about by a polymorphism instead. These problems are addressed, and a more critical evaluation of the underlying genetic data is proposed.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(20)
| Title and authors |
Publication |
Year |
Exacerbation of acetazolamide-responsive sodium channel myotonia by uterotonic agents
K. Fujii, H. Iranami, Y. Hatano
|
International Journal of Obstetric Anesthesia
|
2011 |
Muskuläre Kanalopathien
K. Jurkat-Rott, H. Lerche, F. Lehmann-Horn
|
Nervenarzt
|
2011 |
Divergent biophysical properties, gating mechanisms, and possible functions of the two skeletal muscle CaV1.1 calcium channel splice variants
Bernhard E. Flucher, Petronel Tuluc
|
J Muscle Res Cell Motil
|
2011 |
Cardiac Channelopathies : Applications of Genomics and Proteomics in Diagnosis and Therapy
Cedric Viero
|
OMICS Biomedical Perspectives and Applications
|
2011 |
Channelopathies in Cav1.1, Cav1.3, and Cav1.4 voltage-gated L-type Ca2+ channels.
Jörg Striessnig, Hanno Jörn Bolz, Alexandra Koschak
|
Pflugers Arch.
|
2010 |
Stressed out: the skeletal muscle ryanodine receptor as a target of stress
Andrew M. Bellinger, Marco Mongillo, Andrew R. Marks
|
J. Clin. Invest.
|
2008 |
Mutation analysis of CHRNA1, CHRNB1, CHRND, and RAPSN genes in multiple pterygium syndrome/fetal akinesia patients.
Julie Vogt, Benjamin J Harrison, Hayley Spearman, Judy Cossins, Sascha Vermeer, Lambert Naudin ten Cate, Neil V Morgan, David Beeson, Eamonn R Maher
|
Am. J. Hum. Genet.
|
2008 |
In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with non-dystrophic myotonia
Jeroen Trip, Gea Drost, Dennis J Verbove, Anneke J van der Kooi, Jan B M Kuks, Nicolette C Notermans, Jan J Verschuuren, Marianne de Visser, Baziel G M van Engelen, Carin G Faber, Ieke B Ginjaar
|
Eur J Hum Genet
|
2008 |
Treatment of neuromuscular channelopathies: Current concepts and future prospects
James C. Cleland, Robert C. Griggs
|
Neurotherapeutics
|
2008 |
Epileptogenic Channelopathies: Experimental Models of Human Pathologies
Giuliano Avanzini, Silvana Franceschetti, Massimo Mantegazza
|
Epilepsia
|
2007 |
|